Publications by authors named "T Odagaki"
Article Synopsis
- Pneumothorax, a condition where air leaks into the chest cavity, has been identified as a complication of COVID-19, affecting patients mainly within a month of their diagnosis.
- In a study of 21 patients who developed pneumothorax post-COVID-19, most were elderly males with a history of smoking and common conditions like hypertension and diabetes.
- The treatment for pneumothorax often involved chest drainage, with a mean recovery time of 14 days, but the 30-day mortality rate was notably high at 28.6%, highlighting the seriousness of this complication.
The coronavirus disease 2019 (COVID-19) pandemic has restricted many medical practices. We aimed to investigate the impact of the COVID-19 pandemic on the number of bronchoscopies, outpatients, and hospital admissions. We retrospectively analyzed the number of outpatients, admissions, and bronchoscopies performed between March 2020 and May 2022.
View Article and Find Full Text PDFDetermination of cooperatively rearranging regions in a binary glass former.
J Phys Condens Matter
May 2023
Cooperative motions are important for understanding the divergence of viscosity of glassy materials at a finite temperature, since the elementary process of the structural relaxation occurs within the smallest cooperative region as suggested by Adam and Gibbs. On the basis of the definition of a cooperatively rearranging region (CRR) by Adam and Gibbs and by Odagaki, we determine the size of CRR for the Kob-Andersen model as a function of temperature using molecular dynamics simulations. We first confine particles in a spherical region and, varying the radius of that region, we determine the CRR size as the smallest radius of the region in which particles can change their relative positions.
View Article and Find Full Text PDFThe SIR or susceptible-infected-recovered model is the standard compartment model for understanding epidemics and has been used all over the world for COVID-19. While the SIR model assumes that infected patients are identical to symptomatic and infectious patients, it is now known that in COVID-19 pre-symptomatic patients are infectious and there are significant number of asymptomatic patients who are infectious. In this paper, population is separated into five compartments for COVID-19; susceptible individuals (S), pre-symptomatic patients (P), asymptomatic patients (A), quarantined patients (Q) and recovered and/or dead patients (R).
View Article and Find Full Text PDFBackground: Molnupiravir is being widely used as a treatment for coronavirus disease 2019 (COVID-19); however, its acceptability and safety in older patients aged ≥ 80 years in real-world clinical practice is not well understood.
Methods: We conducted a single-centre retrospective study and assessed the outcome of patients with COVID-19 treated with molnupiravir according to the following criteria: (A) discontinuation rate of molnupiravir; (B) type, frequency, and severity of adverse events; (C) all-cause mortality within 30 days of the diagnosis of COVID-19.
Results: Forty-seven patients (46.